2alpha, 3alpha-epithio-5alpha-androstan-17beta-yl 1-methoxycyclopentyl ether in the treatment of advanced breast cancer: Japanese Cooperative Group of Hormonal Treatment for Breast Cancer.
A new antiestrogenic steroid, 2alpha, 3alpha-epithio-5alpha-androstand-17beta-yl 1-methoxy-cyclopentyl ether, mepitiostane, given orally 10 mg b.i.d. to 50 patients with advanced breast cancer, produced objective regression of the tumor in 17 cases (34%). Objective regression of the metastases was seen in 20 of the 48 control patients given fluoxymesterone, 10 mg b.i.d. orally (47.7%). These figures do not differ significantly. The study was a prospective, randomized, double-blind trial employing the protocol of the Cooperative Breast Cancer Group. There was a significantly lower incidence of hepatotoxicity in the patients given mepitiostane.
D000284:Administration, Oral; D000367:Age Factors; D000731:Androstanes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000732:Androstanols; D001943:Breast Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004965:Estrogen Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005474:Fluoxymesterone / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008099:Liver / Q000187:drug effects; D008593:Menopause; D008875:Middle Aged; D009362:Neoplasm Metastasis; D012075:Remission, Spontaneous; D013440:Sulfides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
D000731:Androstanes; D000732:Androstanols; D004965:Estrogen Antagonists; D013440:Sulfides; D005474:Fluoxymesterone; C006242:mepitiostane